Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 2.7% Today

What is Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company (BMY) is a renowned pharmaceutical company known for its innovative therapies and strong market presence. Today, BMY experienced a significant bullish movement in the stock market.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 2.7% on Jun 26, 2026 14:35

• The bullish movement in BMY's stock is linked to the positive CARVYKTI data released by Legend Biotech, showcasing strong efficacy and safety for multiple myeloma. This promising data has likely boosted investor confidence in Bristol-Myers Squibb's overall pipeline and future revenue potential.
• The surge in Q1 2026 sales reported by Legend Biotech, a subsidiary of Bristol-Myers Squibb, driven by global expansion and improved manufacturing efficiency, has contributed to the bullish sentiment surrounding BMY.
• Analysts who are maintaining a bullish outlook on BMY due to the expanding market opportunity of CARVYKTI and the company's robust financial position further supported the stock's upward movement.
• The positive performance of Astrazeneca (AZN) in the midst of a broader market decline may have also influenced investor sentiment towards pharmaceutical companies like Bristol-Myers Squibb, leading to the bullish movement in BMY's stock.

BMY Price Chart

BMY Technical Analysis

BMY News

What Did the Recent CARVYKTI Data Reveal About Its Potential

Legend Biotech's CARVYKTI demonstrates strong efficacy and safety for multiple myeloma, with recent data supporting its use earlier in treatment. The company reported a significant surge in Q1 2026 sales, driven by global expansion and improved manufacturing efficiency, positioning it for projected company-wide profitability in 2026. Despite competitive pressures and manufacturing challenges, analysts maintain a bullish outlook due to the therapy's expanding market opportunity and Legend Biotech's robust financial position.

https://www.kavout.com/market-lens/what-did-the-recent-carvykti-data-reveal-about-its-potential

Number of shareholders of Bristol-Myers Squibb Company Celegne Contingent Value – BOATS:CELG/R

This article provides information about the number of shareholders for Bristol-Myers Squibb Company's Celgene Contingent Value Rights (CELG/R) on the Blue Ocean Alternative Trade System (BOATS). The page displays that the market is closed, with no trades, and offers sections for overview, financials, news, community, and forecasts related to CELG/R. It also includes standard financial data disclaimers and links to various TradingView products and community features.

https://www.tradingview.com/symbols/BOATS-CELG/R/financials-statistics-and-ratios/number-of-shareholders/

The Escalator: Sanofi, Takeda, EMD Serono and more

This article provides an "Escalator" update on recent leadership changes and significant news across the pharmaceutical, biotech, and medical marketing industries. It details new hires at companies like Sanofi and Klick Health, executive promotions at Takeda and EMD Serono, and notable departures from Pfizer and Sanofi. The report also touches on miscellaneous industry news, including a White House policy aide being considered for the FDA leadership and legal developments involving Bayer and UnitedHealthcare.

https://www.mmm-online.com/news/the-escalator-sanofi-takeda-emd-serono-and-more/

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

Astrazeneca (AZN) closed higher while the broader market declined, showing a +1.45% change. Despite a recent monthly dip, analysts expect a slight EPS decrease but a revenue increase for its upcoming quarterly report. The company currently holds a Zacks Rank of #3 (Hold) and trades at a discounted Forward P/E compared to its industry, suggesting potential value.

https://uk.finance.yahoo.com/news/astrazeneca-azn-ascends-while-market-221505334.html

Price to sales forward of Bristol-Myers Squibb Company Celegne Contingent Value – BOATS:CELG/R

This article provides the "Price to sales forward" financial metric for Bristol-Myers Squibb Company Celegne Contingent Value (CELG/R) on the Blue Ocean Alternative Trade System. The data is presented within the TradingView platform, noting that the market is currently closed with no trades. The content primarily focuses on presenting this specific financial data point for the company.

https://www.tradingview.com/symbols/BOATS-CELG/R/financials-statistics-and-ratios/price-sales-fwd/

Trending Today

Bristol-Myers Squibb Company Price History

30.03.2026 - BMY Stock was up 5.1%

• The bullish movement of BMY could be attributed to the positive outlook surrounding its schizophrenia drug Cobenfy, positioned as a safer alternative for Alzheimer's disease psychosis treatment, potentially attracting investor interest in the company's pipeline and future prospects.
• The delayed pivotal Phase 3 ADEPT-2 study data for Cobenfy, expected later this year, might have created anticipation and excitement among investors, leading to increased buying activity of BMY shares.
• The strong performance of competitors like ALNYLAM PHARMACEUTICALS and Eli Lilly and Company, as indicated by their positive earnings reports and revenue growth, could have positively influenced market sentiment towards pharmaceutical stocks, including BMY, contributing to its bullish movement today.

30.03.2026 - BMY Stock was up 4.5%

• Bristol Myers Squibb (BMY) experienced a strong bullish movement today, likely driven by its higher-than-expected quarterly profit fueled by robust sales of its blood thinner Eliquis and newer cancer treatments.
• The positive market sentiment towards BMY could also be influenced by the reaffirmation of its 2026 financial outlook and progress on a $2 billion cost-cutting program, showcasing strong financial management.
• Additionally, the overall bullish trend in the pharmaceutical sector, as evidenced by Merck's earnings beat and raised guidance, may have contributed to the positive movement in BMY's stock price.
• Investors are likely optimistic about BMY's future prospects, especially with the company's focus on innovative treatments and maintaining a competitive edge in the market.

05.01.2026 - BMY Stock was up 5.7%

• Bristol Myers Squibb's stock surged due to its fourth-quarter earnings surpassing analyst expectations, showcasing a strong financial performance.
• Investor excitement was further boosted by the positive outlook provided by the company, reflecting confidence in its future growth prospects.
• Revenue growth, particularly driven by successful immuno-oncology treatments, helped offset the decline in sales of older drugs, contributing to overall positive market sentiment.
• The impressive performance in Q4 2025 and the promising outlook for 2026 underscored Bristol Myers Squibb's resilience in adapting to market changes and solidifying its position in the pharmaceutical industry.

05.01.2026 - BMY Stock was up 3.2%

• Despite disappointments with Eliquis and Cobenfy, Bristol Myers Squibb's strong fourth-quarter earnings report and revenue beat have propelled its stock to a bullish movement.
• The company's focus on its Growth Portfolio, featuring drugs like Opdivo and Reblozyl, has driven significant revenue growth and instilled confidence in investors.
• Bristol Myers Squibb's strategic approach to leaning on new products and potential M&A opportunities to expand its therapeutic areas has resonated well with the market, leading to the positive market movement.
• The company's ability to exceed analyst expectations and provide an optimistic outlook for future revenues has further fueled investor excitement and contributed to the bullish trend in its stock price.

03.11.2025 - BMY Stock was up 5.5%

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

03.11.2025 - BMY Stock was up 5.1%

• BMY's stock surged after a positive update on its late-stage clinical trial for treating psychosis associated with Alzheimer’s disease, signaling progress in its research endeavors.
• A collaboration milestone with Terray Therapeutics highlights BMY's utilization of AI-enabled drug discovery technologies to accelerate small molecule drug development, potentially enhancing investor confidence.
• Despite delays in the Adept-2 study for Cobenfy in Alzheimer's psychosis, efforts to rectify site irregularities and continue enrolling new patients demonstrate BMY's commitment to upholding clinical standards and addressing medical needs, possibly contributing to the stock's bullish performance.

05.00.2026 - BMY Stock was down 1.7%

• Increased investments by Railway Pension Investments Ltd and CWA Asset Management Group LLC in Bristol Myers Squibb (BMY) may have hinted at uncertainties about the company's future performance, influencing the bearish trajectory.
• While Bristol Myers Squibb exceeded Q3 earnings and revenue projections and raised its dividend, market sentiments may have been dampened by apprehensions regarding the company's growth outlook.
• Favorable results from Zenas BioPharma's Phase 3 trial and the thriving Hair Loss Treatment Market could have drawn investor attention away from Bristol Myers Squibb, impacting its stock trajectory.
• The optimistic forecast for the pharmaceutical sector, evidenced by growth prospects in the aminoglycosides market, might have steered investor focus elsewhere from Bristol Myers Squibb, contributing to the downward movement in its stock.

20.02.2026 - BMY Stock was down 2.7%

• Union Bancaire Privee UBP SA, Mirabella Financial Services LLP, and CIBC Bancorp USA Inc. all increased their stakes in BMY, signaling confidence in the company's long-term prospects despite recent stock price fluctuations.
• Bristol Myers Squibb reported quarterly earnings that missed analyst estimates but maintained its full-year EPS guidance and announced a quarterly dividend, which might have contributed to the bearish market movement.
• The news about ImmunityBio's cancer therapy Anktiva gaining recognition and Evotec's AI-driven research reaching a critical milestone with a drug developed in partnership with BMY could have diverted investor attention from BMY, impacting its stock performance negatively.
• Despite positive developments in the healthcare sector, including advancements in cancer therapies, BMY's stock faced downward pressure, possibly due to profit-taking or market uncertainties surrounding its recent financial results.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

06.01.2026 - BMY Stock was up 5.1%

• Despite industry challenges, Bristol Myers Squibb (BMY) saw a strong bullish movement in its stock price.
• Investor optimism towards BMY is likely driven by the company surpassing analysts' expectations for adjusted earnings and revenue in the fourth quarter.
• The positive sentiment towards BMY could also be linked to the upcoming conference call to discuss financial results, hinting at potential positive developments or strategic plans.
• This upward trend may indicate that investors are focusing on Bristol Myers Squibb's resilience and ability to navigate industry challenges, rather than broader market uncertainties impacting other pharmaceutical companies.

26.05.2026 - BMY Stock was up 2.7%

• The bullish movement in BMY's stock is linked to the positive CARVYKTI data released by Legend Biotech, showcasing strong efficacy and safety for multiple myeloma. This promising data has likely boosted investor confidence in Bristol-Myers Squibb's overall pipeline and future revenue potential.
• The surge in Q1 2026 sales reported by Legend Biotech, a subsidiary of Bristol-Myers Squibb, driven by global expansion and improved manufacturing efficiency, has contributed to the bullish sentiment surrounding BMY.
• Analysts who are maintaining a bullish outlook on BMY due to the expanding market opportunity of CARVYKTI and the company's robust financial position further supported the stock's upward movement.
• The positive performance of Astrazeneca (AZN) in the midst of a broader market decline may have also influenced investor sentiment towards pharmaceutical companies like Bristol-Myers Squibb, leading to the bullish movement in BMY's stock.

06.00.2026 - BMY Stock was up 5.1%

• A recent collaboration between Gilead and OncoNano Medicine utilizing OncoNano's drug delivery platform may have attracted investor interest in the pharmaceutical sector, benefiting companies like Bristol Myers Squibb.
• Robeco Institutional Asset Management B.V. raised its stake in BMY by 6.4% during the 3rd quarter, indicating a growing confidence in the company's future prospects, potentially influencing the bullish movement.
• Despite some reduction in BMY position by D.A. Davidson & CO., the overall positive sentiment towards the company, especially post exceeding earnings estimates and offering strong guidance, likely overshadowed this sell-off.
• The comparison between Zenas Biopharma's obexelimab and Amgen's Uplizna in the Phase 3 trial may have highlighted Bristol Myers Squibb's competitive edge or potential in the pharmaceutical market, fueling investor optimism and driving the stock price upwards.